Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Arthroplasty

In brief

Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement

Key facts

Study ID

NCT00683267

Run by

Anesiva, Inc.

People needed

118

Starts

2007-09-01

Expected to finish

2008-12-01

Last updated by the study team

2009-05-04

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Alabama Clinical Therapeutics, LLC — Birmingham, Alabama, United States
• Lotus Clinical Research, Inc. — Arcadia, California, United States
• Glendale Adventist Medical Center — Glendale, California, United States
• Webster Orthopaedic Medical Group — Oakland, California, United States
• University of California at San Francisco - Mt. Zion — San Francisco, California, United States
• Coastal Medical Research, Inc. — Port Orange, Florida, United States
• William Beaumont Hospital — Royal Oak, Michigan, United States
• William Beaumont Hospital — Troy, Michigan, United States
• Sewickley Valley Hospial — Sewickley, Pennsylvania, United States
• Covenant Medical Center — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.